Mechanisms of resistance to rapamycins

Shile Huang, Peter J Houghton

Research output: Contribution to journalReview article

115 Citations (Scopus)

Abstract

Rapamycins represent a novel family of anticancer agents, currently including rapamycin and its derivatives, CCI-779 and RAD001. Rapamycins inhibit the function of the mammalian target of rapamycin (mTOR), and potently suppress tumor cell growth by arresting cells in GI phase or potentially inducing apoptosis of cells, in culture or in xenograft tumor models. However, recent data indicate that genetic mutations or compensatory changes in tumor cells influence the sensitivity of rapamycins. First, mutations of mTOR or FKBPI2 prevent rapamycin from binding to mTOR, conferring rapamycin resistance. Second, mutations or defects of mTOR-regulated proteins, including S6KI, 4E-BPI, PP2A-related phosphatases, and p27Kipl also render rapamycin insensitivity. In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity. To better explore the role of rapamycins against tumors, this review will summarize the current knowledge of the mechanism of action of rapamycins, and progress in understanding mechanisms of acquired or intrinsic resistance.

Original languageEnglish (US)
Pages (from-to)378-391
Number of pages14
JournalDrug Resistance Updates
Volume4
Issue number6
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Sirolimus
Mutation
Neoplasms
TOR Serine-Threonine Kinases
Phosphoric Monoester Hydrolases
Heterografts
Antineoplastic Agents
Cell Culture Techniques
Apoptosis

Keywords

  • Drug resistance
  • MTOR
  • P27
  • Rapamycin
  • Signaling pathways

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Mechanisms of resistance to rapamycins. / Huang, Shile; Houghton, Peter J.

In: Drug Resistance Updates, Vol. 4, No. 6, 01.01.2001, p. 378-391.

Research output: Contribution to journalReview article

Huang, Shile ; Houghton, Peter J. / Mechanisms of resistance to rapamycins. In: Drug Resistance Updates. 2001 ; Vol. 4, No. 6. pp. 378-391.
@article{cba308b9a69f4955bb957c7f87f26723,
title = "Mechanisms of resistance to rapamycins",
abstract = "Rapamycins represent a novel family of anticancer agents, currently including rapamycin and its derivatives, CCI-779 and RAD001. Rapamycins inhibit the function of the mammalian target of rapamycin (mTOR), and potently suppress tumor cell growth by arresting cells in GI phase or potentially inducing apoptosis of cells, in culture or in xenograft tumor models. However, recent data indicate that genetic mutations or compensatory changes in tumor cells influence the sensitivity of rapamycins. First, mutations of mTOR or FKBPI2 prevent rapamycin from binding to mTOR, conferring rapamycin resistance. Second, mutations or defects of mTOR-regulated proteins, including S6KI, 4E-BPI, PP2A-related phosphatases, and p27Kipl also render rapamycin insensitivity. In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity. To better explore the role of rapamycins against tumors, this review will summarize the current knowledge of the mechanism of action of rapamycins, and progress in understanding mechanisms of acquired or intrinsic resistance.",
keywords = "Drug resistance, MTOR, P27, Rapamycin, Signaling pathways",
author = "Shile Huang and Houghton, {Peter J}",
year = "2001",
month = "1",
day = "1",
doi = "10.1054/drup.2002.0227",
language = "English (US)",
volume = "4",
pages = "378--391",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Mechanisms of resistance to rapamycins

AU - Huang, Shile

AU - Houghton, Peter J

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Rapamycins represent a novel family of anticancer agents, currently including rapamycin and its derivatives, CCI-779 and RAD001. Rapamycins inhibit the function of the mammalian target of rapamycin (mTOR), and potently suppress tumor cell growth by arresting cells in GI phase or potentially inducing apoptosis of cells, in culture or in xenograft tumor models. However, recent data indicate that genetic mutations or compensatory changes in tumor cells influence the sensitivity of rapamycins. First, mutations of mTOR or FKBPI2 prevent rapamycin from binding to mTOR, conferring rapamycin resistance. Second, mutations or defects of mTOR-regulated proteins, including S6KI, 4E-BPI, PP2A-related phosphatases, and p27Kipl also render rapamycin insensitivity. In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity. To better explore the role of rapamycins against tumors, this review will summarize the current knowledge of the mechanism of action of rapamycins, and progress in understanding mechanisms of acquired or intrinsic resistance.

AB - Rapamycins represent a novel family of anticancer agents, currently including rapamycin and its derivatives, CCI-779 and RAD001. Rapamycins inhibit the function of the mammalian target of rapamycin (mTOR), and potently suppress tumor cell growth by arresting cells in GI phase or potentially inducing apoptosis of cells, in culture or in xenograft tumor models. However, recent data indicate that genetic mutations or compensatory changes in tumor cells influence the sensitivity of rapamycins. First, mutations of mTOR or FKBPI2 prevent rapamycin from binding to mTOR, conferring rapamycin resistance. Second, mutations or defects of mTOR-regulated proteins, including S6KI, 4E-BPI, PP2A-related phosphatases, and p27Kipl also render rapamycin insensitivity. In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity. To better explore the role of rapamycins against tumors, this review will summarize the current knowledge of the mechanism of action of rapamycins, and progress in understanding mechanisms of acquired or intrinsic resistance.

KW - Drug resistance

KW - MTOR

KW - P27

KW - Rapamycin

KW - Signaling pathways

UR - http://www.scopus.com/inward/record.url?scp=0035744033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035744033&partnerID=8YFLogxK

U2 - 10.1054/drup.2002.0227

DO - 10.1054/drup.2002.0227

M3 - Review article

C2 - 12030785

AN - SCOPUS:0035744033

VL - 4

SP - 378

EP - 391

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 6

ER -